$ASMB
Assembly Biosciences Inc

2024 Q3 Form 10-Q Financial Statement

#000095017024093998 Filed on August 08, 2024

View on sec.gov

Income Statement

Concept 2024 Q3 2024 Q2 2023 Q2
Revenue $6.845M $8.533M $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $4.477M $4.970M
YoY Change -9.92% -26.71%
% of Gross Profit
Research & Development $13.52M $16.26M $12.52M
YoY Change 24.86% 29.83% -29.61%
% of Gross Profit
Depreciation & Amortization $32.00K $126.0K
YoY Change -74.6% 5.0%
% of Gross Profit
Operating Expenses $17.80M $20.74M $17.49M
YoY Change 18.29% 18.57% -28.83%
Operating Profit -$10.96M -$12.20M -$17.49M
YoY Change -27.19% -30.22% -28.83%
Interest Expense $1.457M $590.0K
YoY Change 146.95% 426.79%
% of Operating Profit
Other Income/Expense, Net $1.343M $1.457M $592.0K
YoY Change 113.85% 146.11% 428.57%
Pretax Income -$9.613M -$10.75M -$16.90M
YoY Change -33.34% -36.41% -30.91%
Income Tax $0.00 $406.0K $0.00
% Of Pretax Income
Net Earnings -$9.613M -$11.15M -$16.90M
YoY Change -33.34% -34.0% -30.93%
Net Earnings / Revenue -140.44% -130.69%
Basic Earnings Per Share -$1.51 -$1.98 -$0.32
Diluted Earnings Per Share -$1.51 -$1.98 -$0.32
COMMON SHARES
Basic Shares Outstanding 6.346M 5.513M 52.12M
Diluted Shares Outstanding 6.351M 5.643M 52.26M

Balance Sheet

Concept 2024 Q3 2024 Q2 2023 Q2
SHORT-TERM ASSETS
Cash & Short-Term Investments $94.95M $109.2M $59.83M
YoY Change 105.48% 82.55% -48.73%
Cash & Equivalents $28.45M $19.21M $21.62M
Short-Term Investments $66.50M $90.01M $38.21M
Other Short-Term Assets $3.712M $3.908M
YoY Change -5.02% -44.82%
Inventory
Prepaid Expenses
Receivables $0.00 $0.00 $342.0K
Other Receivables $0.00 $0.00
Total Short-Term Assets $98.21M $112.9M $64.08M
YoY Change 97.72% 76.23% -48.44%
LONG-TERM ASSETS
Property, Plant & Equipment $316.0K $349.0K $541.0K
YoY Change -43.67% -35.49% -90.36%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets $312.0K $312.0K $332.0K
YoY Change -43.48% -6.02% -79.69%
Total Long-Term Assets $2.049M $2.392M $2.496M
YoY Change 4.7% -4.17% -86.97%
TOTAL ASSETS
Total Short-Term Assets $98.21M $112.9M $64.08M
Total Long-Term Assets $2.049M $2.392M $2.496M
Total Assets $100.3M $115.3M $66.58M
YoY Change 94.2% 73.22% -53.59%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $1.335M $801.0K $904.0K
YoY Change 76.12% -11.39% -63.16%
Accrued Expenses $4.765M $3.587M $4.188M
YoY Change 22.62% -14.35% -66.51%
Deferred Revenue $32.62M $33.06M
YoY Change
Short-Term Debt $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $41.64M $41.27M $8.831M
YoY Change 483.78% 367.38% -40.97%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00
YoY Change
Other Long-Term Liabilities $39.37M $2.797M
YoY Change 1307.47% -37.93%
Total Long-Term Liabilities $39.37M $2.797M
YoY Change 1307.47% -37.93%
TOTAL LIABILITIES
Total Short-Term Liabilities $41.64M $41.27M $8.831M
Total Long-Term Liabilities $39.37M $2.797M
Total Liabilities $74.26M $80.64M $11.63M
YoY Change 648.96% 593.51% -40.27%
SHAREHOLDERS EQUITY
Retained Earnings -$815.6M -$806.0M -$760.4M
YoY Change 5.27% 6.0%
Common Stock $841.7M $841.0M $815.6M
YoY Change 3.06% 3.1%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $26.00M $34.68M $54.95M
YoY Change
Total Liabilities & Shareholders Equity $100.3M $115.3M $66.58M
YoY Change 94.2% 73.22% -53.59%

Cashflow Statement

Concept 2024 Q3 2024 Q2 2023 Q2
OPERATING ACTIVITIES
Net Income -$9.613M -$11.15M -$16.90M
YoY Change -33.34% -34.0% -30.93%
Depreciation, Depletion And Amortization $32.00K $126.0K
YoY Change -74.6% 5.0%
Cash From Operating Activities -$17.10M -$13.63M
YoY Change 25.49% -23.8%
INVESTING ACTIVITIES
Capital Expenditures $14.00K $48.00K
YoY Change -70.83%
Acquisitions
YoY Change
Other Investing Activities $5.121M -$8.317M
YoY Change -161.57% -186.66%
Cash From Investing Activities $5.107M -$8.365M
YoY Change -161.05% -187.16%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 12.45M 134.0K
YoY Change 9194.03% -24.29%
NET CHANGE
Cash From Operating Activities -17.10M -13.63M
Cash From Investing Activities 5.107M -8.365M
Cash From Financing Activities 12.45M 134.0K
Net Change In Cash 459.0K -21.86M
YoY Change -102.1% 169.5%
FREE CASH FLOW
Cash From Operating Activities -$17.10M -$13.63M
Capital Expenditures $14.00K $48.00K
Free Cash Flow -$17.12M -$13.68M
YoY Change 25.15% -23.53%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
dei Entity Central Index Key
EntityCentralIndexKey
0001426800
dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
Q2
dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
dei Amendment Flag
AmendmentFlag
false
CY2024Q2 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2023Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
CY2024Q2 us-gaap Preferred Stock Value
PreferredStockValue
CY2023Q4 us-gaap Preferred Stock Value
PreferredStockValue
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0833
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0833
CY2024Q1 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.0833
CY2024Q2 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#CashEquivalentsMember
CY2024Q2 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#CashEquivalentsMember
CY2024Q2 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#CashEquivalentsMember
CY2024Q2 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#CashEquivalentsMember
CY2023Q4 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#CashEquivalentsMember
CY2023Q4 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#CashEquivalentsMember
CY2023Q4 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#CashEquivalentsMember
CY2023Q4 us-gaap Investment Type Extensible Enumeration
InvestmentTypeExtensibleEnumeration
http://fasb.org/us-gaap/2024#CashEquivalentsMember
dei Document Type
DocumentType
10-Q
dei Document Quarterly Report
DocumentQuarterlyReport
true
dei Document Period End Date
DocumentPeriodEndDate
2024-06-30
dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2024
dei Document Transition Report
DocumentTransitionReport
false
dei Entity File Number
EntityFileNumber
001-35005
dei Entity Registrant Name
EntityRegistrantName
ASSEMBLY BIOSCIENCES, INC.
dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
dei Entity Tax Identification Number
EntityTaxIdentificationNumber
20-8729264
dei Entity Address Address Line1
EntityAddressAddressLine1
Two Tower Place
dei Entity Address Address Line2
EntityAddressAddressLine2
7th Floor
dei Entity Address City Or Town
EntityAddressCityOrTown
South San Francisco
dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94080
dei City Area Code
CityAreaCode
833
dei Local Phone Number
LocalPhoneNumber
509-4583
dei Security12b Title
Security12bTitle
Common Stock, par value $0.001
dei Trading Symbol
TradingSymbol
ASMB
dei Security Exchange Name
SecurityExchangeName
NASDAQ
dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
dei Entity Small Business
EntitySmallBusiness
true
dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
false
dei Entity Shell Company
EntityShellCompany
false
CY2024Q3 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
6345561
CY2024Q2 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19208000
CY2023Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
19841000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
90011000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
110406000
CY2024Q2 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
0
CY2023Q4 us-gaap Accounts Receivable Net Current
AccountsReceivableNetCurrent
43000
CY2024Q2 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3712000
CY2023Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
3497000
CY2024Q2 us-gaap Assets Current
AssetsCurrent
112931000
CY2023Q4 us-gaap Assets Current
AssetsCurrent
133787000
CY2024Q2 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
349000
CY2023Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
385000
CY2024Q2 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1731000
CY2023Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2339000
CY2024Q2 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
312000
CY2023Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
312000
CY2024Q2 us-gaap Assets
Assets
115323000
CY2023Q4 us-gaap Assets
Assets
136823000
CY2024Q2 us-gaap Accounts Payable Current
AccountsPayableCurrent
801000
CY2023Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
461000
CY2024Q2 asmb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
2531000
CY2023Q4 asmb Accrued Research And Development Expenses Current
AccruedResearchAndDevelopmentExpensesCurrent
885000
CY2024Q2 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
3587000
CY2023Q4 us-gaap Other Accrued Liabilities Current
OtherAccruedLiabilitiesCurrent
5744000
CY2024Q2 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
33060000
CY2023Q4 us-gaap Contract With Customer Liability Current
ContractWithCustomerLiabilityCurrent
30915000
CY2024Q2 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1295000
CY2023Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
1220000
CY2024Q2 us-gaap Liabilities Current
LiabilitiesCurrent
41274000
CY2023Q4 us-gaap Liabilities Current
LiabilitiesCurrent
39225000
CY2024Q2 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
38916000
CY2023Q4 us-gaap Contract With Customer Liability Noncurrent
ContractWithCustomerLiabilityNoncurrent
55379000
CY2024Q2 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
451000
CY2023Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
1122000
CY2024Q2 us-gaap Liabilities
Liabilities
80641000
CY2023Q4 us-gaap Liabilities
Liabilities
95726000
CY2024Q2 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2023Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
5000000
CY2024Q2 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2023Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2024Q2 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2023Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2024Q2 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2023Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.001
CY2024Q2 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2023Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
150000000
CY2024Q2 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
6345561
CY2024Q2 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
6345561
CY2023Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
5482752
CY2023Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
5482752
CY2024Q2 us-gaap Common Stock Value
CommonStockValue
6000
CY2023Q4 us-gaap Common Stock Value
CommonStockValue
5000
CY2024Q2 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
840946000
CY2023Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
826921000
CY2024Q2 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-293000
CY2023Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
-81000
CY2024Q2 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-805977000
CY2023Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-785748000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
34682000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
41097000
CY2024Q2 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
115323000
CY2023Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
136823000
CY2024Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
8533000
CY2023Q2 us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
14318000
us-gaap Revenue From Contract With Customer Including Assessed Tax
RevenueFromContractWithCustomerIncludingAssessedTax
0
CY2024Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
16259000
CY2023Q2 us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
12523000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
28138000
us-gaap Research And Development Expense
ResearchAndDevelopmentExpense
27070000
CY2024Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4477000
CY2023Q2 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
4965000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9112000
us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
9977000
CY2024Q2 us-gaap Operating Expenses
OperatingExpenses
20736000
CY2023Q2 us-gaap Operating Expenses
OperatingExpenses
17488000
us-gaap Operating Expenses
OperatingExpenses
37250000
us-gaap Operating Expenses
OperatingExpenses
37047000
CY2024Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-12203000
CY2023Q2 us-gaap Operating Income Loss
OperatingIncomeLoss
-17488000
us-gaap Operating Income Loss
OperatingIncomeLoss
-22932000
us-gaap Operating Income Loss
OperatingIncomeLoss
-37047000
CY2024Q2 us-gaap Interest Income Other
InterestIncomeOther
1457000
CY2023Q2 us-gaap Interest Income Other
InterestIncomeOther
592000
us-gaap Interest Income Other
InterestIncomeOther
3109000
us-gaap Interest Income Other
InterestIncomeOther
1201000
CY2024Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1457000
CY2023Q2 us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
592000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
3109000
us-gaap Nonoperating Income Expense
NonoperatingIncomeExpense
1201000
CY2024Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-10746000
CY2023Q2 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-16896000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-19823000
us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-35846000
CY2024Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
406000
CY2023Q2 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
406000
us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
0
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11152000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-16896000
us-gaap Net Income Loss
NetIncomeLoss
-20229000
us-gaap Net Income Loss
NetIncomeLoss
-35846000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-54000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
188000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-212000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
478000
CY2024Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-11206000
CY2023Q2 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-16708000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-20441000
us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-35368000
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.98
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.98
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.88
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.33
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5642752
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5642752
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4355007
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4355007
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5563033
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5563033
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4303244
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4303244
CY2024Q1 us-gaap Stockholders Equity
StockholdersEquity
32601000
CY2024Q2 asmb Issuance Of Common Stock And Warrants In Registered Direct Offering And Private Placement Net Of Issuance Costs Value
IssuanceOfCommonStockAndWarrantsInRegisteredDirectOfferingAndPrivatePlacementNetOfIssuanceCostsValue
12395000
CY2024Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
55000
CY2024Q2 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
CY2024Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-54000
CY2024Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
833000
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11152000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
34682000
CY2023Q1 us-gaap Stockholders Equity
StockholdersEquity
70333000
CY2023Q2 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
54000
CY2023Q2 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
80000
CY2023Q2 us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
188000
CY2023Q2 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1190000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-16896000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
54949000
CY2023Q4 us-gaap Stockholders Equity
StockholdersEquity
41097000
asmb Issuance Of Common Stock And Warrants In Registered Direct Offering And Private Placement Net Of Issuance Costs Value
IssuanceOfCommonStockAndWarrantsInRegisteredDirectOfferingAndPrivatePlacementNetOfIssuanceCostsValue
12395000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
55000
us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
4000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
-212000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
1572000
us-gaap Net Income Loss
NetIncomeLoss
-20229000
CY2024Q2 us-gaap Stockholders Equity
StockholdersEquity
34682000
CY2022Q4 us-gaap Stockholders Equity
StockholdersEquity
82664000
us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
4546000
us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
80000
us-gaap Other Comprehensive Income Unrealized Holding Gain Loss On Securities Arising During Period Net Of Tax
OtherComprehensiveIncomeUnrealizedHoldingGainLossOnSecuritiesArisingDuringPeriodNetOfTax
478000
us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
3027000
us-gaap Net Income Loss
NetIncomeLoss
-35846000
CY2023Q2 us-gaap Stockholders Equity
StockholdersEquity
54949000
us-gaap Profit Loss
ProfitLoss
-20229000
us-gaap Profit Loss
ProfitLoss
-35846000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
64000
us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
250000
us-gaap Share Based Compensation
ShareBasedCompensation
1572000
us-gaap Share Based Compensation
ShareBasedCompensation
3025000
asmb Accretion Amortization Of Investments In Marketable Debt Securities
AccretionAmortizationOfInvestmentsInMarketableDebtSecurities
2224000
asmb Accretion Amortization Of Investments In Marketable Debt Securities
AccretionAmortizationOfInvestmentsInMarketableDebtSecurities
221000
asmb Noncash Rent Expense
NoncashRentExpense
713000
asmb Noncash Rent Expense
NoncashRentExpense
1709000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-43000
us-gaap Increase Decrease In Accounts Receivable
IncreaseDecreaseInAccountsReceivable
-602000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
215000
us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
-505000
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
0
us-gaap Increase Decrease In Other Noncurrent Assets
IncreaseDecreaseInOtherNoncurrentAssets
-557000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
340000
us-gaap Increase Decrease In Accounts Payable
IncreaseDecreaseInAccountsPayable
-1589000
asmb Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
1646000
asmb Increase Decrease In Accrued Research And Development Expenses
IncreaseDecreaseInAccruedResearchAndDevelopmentExpenses
-1085000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-2157000
us-gaap Increase Decrease In Other Accrued Liabilities
IncreaseDecreaseInOtherAccruedLiabilities
-3127000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
-14318000
us-gaap Increase Decrease In Contract With Customer Liability
IncreaseDecreaseInContractWithCustomerLiability
0
asmb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-701000
asmb Increase Decrease In Operating Lease Liabilities
IncreaseDecreaseInOperatingLeaseLiabilities
-1836000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-35466000
us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-37056000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
57300000
us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
24645000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
34893000
us-gaap Payments To Acquire Available For Sale Securities Debt
PaymentsToAcquireAvailableForSaleSecuritiesDebt
22962000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
28000
us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
48000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
22379000
us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
1635000
asmb Proceeds From Issuance Of Common Stock And Warrants In Registered Direct Offering And Private Placement Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsInRegisteredDirectOfferingAndPrivatePlacementNetOfIssuanceCosts
12395000
asmb Proceeds From Issuance Of Common Stock And Warrants In Registered Direct Offering And Private Placement Net Of Issuance Costs
ProceedsFromIssuanceOfCommonStockAndWarrantsInRegisteredDirectOfferingAndPrivatePlacementNetOfIssuanceCosts
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
0
us-gaap Proceeds From Issuance Of Common Stock
ProceedsFromIssuanceOfCommonStock
4546000
asmb Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
55000
asmb Proceeds From Issuance Of Common Stock Under Employee Stock Purchase Plan
ProceedsFromIssuanceOfCommonStockUnderEmployeeStockPurchasePlan
80000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
4000
us-gaap Proceeds From Stock Options Exercised
ProceedsFromStockOptionsExercised
0
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
12454000
us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
4626000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-633000
us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-30795000
CY2023Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19841000
CY2022Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
52418000
CY2024Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
19208000
CY2023Q2 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
21623000
us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
asmb Number Of Approved Products
NumberOfApprovedProducts
0
us-gaap Use Of Estimates
UseOfEstimates
<p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-weight:bold;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Use of Estimates</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The preparation of the unaudited condensed consolidated financial statements in conformity with U.S. GAAP requires management to make estimates and assumptions that may affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the financial statements and reported amounts of expenses during the reporting period. Actual results could differ from those estimates.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">Significant estimates inherent in the preparation of the accompanying unaudited condensed consolidated financial statements include estimates for revenue recognition and costs incurred but not yet invoiced for research and development accruals.</span></p><p style="font-size:10pt;margin-top:10pt;font-family:Times New Roman;margin-bottom:0;text-align:justify;"><span style="color:#000000;white-space:pre-wrap;font-size:10pt;font-family:Times New Roman;min-width:fit-content;">The Company’s estimates could be affected by external conditions, including those unique to the Company and general economic conditions. It is reasonably possible these external factors could have an effect on the Company’s estimates and could cause actual results to differ materially from those estimates and assumptions.</span></p>
us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
In January 2024, the Company's stockholders approved a reverse stock split of its common stock at a range of ratios between 1-for-7 to 1-for-17, and the Company's board of directors approved the implementation of the reverse stock split at a ratio of 1-for-12 (the Reverse Stock Split). The Reverse Stock Split was effective as of February 9, 2024 and the Company regained compliance with the minimum bid price requirement in February 2024.
CY2024Q1 asmb Stock Outstanding During Period Shares Reverse Stock Splits
StockOutstandingDuringPeriodSharesReverseStockSplits
65800000
CY2024Q1 asmb Stock Outstanding During Period Shares Reverse Stock Splits
StockOutstandingDuringPeriodSharesReverseStockSplits
5500000
CY2024Q1 us-gaap Stock Issued During Period Shares Reverse Stock Splits
StockIssuedDuringPeriodSharesReverseStockSplits
0
CY2024Q2 us-gaap Net Income Loss
NetIncomeLoss
-11152000
CY2023Q2 us-gaap Net Income Loss
NetIncomeLoss
-16896000
us-gaap Net Income Loss
NetIncomeLoss
-20229000
us-gaap Net Income Loss
NetIncomeLoss
-35846000
CY2024Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5642752
CY2024Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5642752
CY2023Q2 us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4355007
CY2023Q2 us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4355007
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
5563033
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
5563033
us-gaap Weighted Average Number Of Shares Outstanding Basic
WeightedAverageNumberOfSharesOutstandingBasic
4303244
us-gaap Weighted Average Number Of Diluted Shares Outstanding
WeightedAverageNumberOfDilutedSharesOutstanding
4303244
CY2024Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-1.98
CY2024Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-1.98
CY2023Q2 us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.88
CY2023Q2 us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.88
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-3.64
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-3.64
us-gaap Earnings Per Share Basic
EarningsPerShareBasic
-8.33
us-gaap Earnings Per Share Diluted
EarningsPerShareDiluted
-8.33
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
1900374
us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
966704
CY2024Q2 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
18601000
CY2024Q2 asmb Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0
CY2024Q2 asmb Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
0
CY2024Q2 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
18601000
CY2024Q2 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
90031000
CY2024Q2 asmb Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
3000
CY2024Q2 asmb Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
23000
CY2024Q2 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
90011000
CY2024Q2 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
108632000
CY2024Q2 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
3000
CY2024Q2 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss
23000
CY2024Q2 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
108612000
CY2023Q4 us-gaap Cash Equivalents At Carrying Value
CashEquivalentsAtCarryingValue
18982000
CY2023Q4 asmb Cash And Cash Equivalent Gross Unrealized Gain
CashAndCashEquivalentGrossUnrealizedGain
0
CY2023Q4 asmb Cash And Cash Equivalent Gross Unrealized Loss
CashAndCashEquivalentGrossUnrealizedLoss
0
CY2023Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
18982000
CY2023Q4 us-gaap Debt Securities Available For Sale Amortized Cost Current
DebtSecuritiesAvailableForSaleAmortizedCostCurrent
110214000
CY2023Q4 asmb Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTaxCurrent
195000
CY2023Q4 asmb Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax Current
AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTaxCurrent
3000
CY2023Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
110406000
CY2023Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Amortized Cost
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesAmortizedCost
129196000
CY2023Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Gain
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedGain
195000
CY2023Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Gross Unrealized Loss
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesGrossUnrealizedLoss
3000
CY2023Q4 asmb Cash Equivalents At Carrying Value And Available For Sale Debt Securities Estimated Fair Value
CashEquivalentsAtCarryingValueAndAvailableForSaleDebtSecuritiesEstimatedFairValue
129388000
CY2024Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2023Q2 us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
us-gaap Realized Investment Gains Losses
RealizedInvestmentGainsLosses
0
CY2024Q2 asmb Accured Interest Receivable
AccuredInterestReceivable
400000
CY2023Q4 asmb Accured Interest Receivable
AccuredInterestReceivable
300000
CY2024Q2 asmb Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
0
CY2023Q4 asmb Fair Value Assets Between Levels Transfers Amount
FairValueAssetsBetweenLevelsTransfersAmount
0
CY2024Q2 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2791000
CY2023Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
5484000
CY2024Q2 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
796000
CY2023Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
260000
CY2024Q2 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
3587000
CY2023Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
5744000
CY2024Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
833000
CY2023Q2 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1190000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
1572000
us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
3025000
CY2024Q2 us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Share Based Awards Other Than Options
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedShareBasedAwardsOtherThanOptions
3700000
us-gaap Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1
EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1
P1Y8M12D
CY2023Q2 asmb Share Based Compensation Arrangement Fair Value Assumptions Exercise Price
ShareBasedCompensationArrangementFairValueAssumptionsExercisePrice
11.64
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate
0.776
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate
0.0382
CY2023Q2 us-gaap Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1
SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1
P7Y6M
CY2024Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q2 us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
us-gaap Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate
ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate
0
CY2023Q4 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
86294000
asmb Contract With Customer Liability In Additions
ContractWithCustomerLiabilityInAdditions
0
asmb Contract With Customer Liability In Deduction
ContractWithCustomerLiabilityInDeduction
14318000
CY2024Q2 us-gaap Contract With Customer Liability
ContractWithCustomerLiability
71976000
CY2024Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
8533000
CY2023Q2 us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
14318000
us-gaap Contract With Customer Liability Revenue Recognized
ContractWithCustomerLiabilityRevenueRecognized
0
CY2024Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2023Q2 us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
us-gaap Contract With Customer Performance Obligation Satisfied In Previous Period
ContractWithCustomerPerformanceObligationSatisfiedInPreviousPeriod
0
CY2024Q2 us-gaap Purchase Commitment Remaining Minimum Amount Committed
PurchaseCommitmentRemainingMinimumAmountCommitted
800000
CY2024Q2 asmb Milestone Payment Diligence Maintenance Fees
MilestonePaymentDiligenceMaintenanceFees
0
CY2023Q2 asmb Milestone Payment Diligence Maintenance Fees
MilestonePaymentDiligenceMaintenanceFees
0
asmb Milestone Payment Diligence Maintenance Fees
MilestonePaymentDiligenceMaintenanceFees
100000
asmb Milestone Payment Diligence Maintenance Fees
MilestonePaymentDiligenceMaintenanceFees
100000

Files In Submission

Name View Source Status
0000950170-24-093998-index-headers.html Edgar Link pending
0000950170-24-093998-index.html Edgar Link pending
0000950170-24-093998.txt Edgar Link pending
0000950170-24-093998-xbrl.zip Edgar Link pending
asmb-20240630.htm Edgar Link pending
asmb-20240630.xsd Edgar Link pending
asmb-ex31_1.htm Edgar Link pending
asmb-ex32_1.htm Edgar Link pending
Financial_Report.xlsx Edgar Link pending
MetaLinks.json Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
asmb-20240630_htm.xml Edgar Link completed
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R5.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending